Tech Company Financing Transactions

Xilio Therapeutics Funding Round

Xilio Therapeutics secured a $100.5 million Series B funding round on 3/3/2020. Investors included Takeda Ventures, Atlas Venture and Bay City Capital.

Transaction Overview

Company Name
Xilio Therapeutics
Announced On
3/3/2020
Transaction Type
Venture Equity
Amount
$100,500,000
Round
Series B
Investors

Takeda Ventures (Lead Investor) (Jayson Punwani)

Atlas Venture (David Grayzel)

Bay City Capital

F-Prime Capital (Benjamin Auspitz)

Ipsen

M Capital

MRL Ventures (Peter Dudek)

RiverVest Venture Partners (Nancy Hong)

Solasta Ventures

SV Health Investors (Michael Ross)

Proceeds Purpose
Proceeds from the financing will be used to progress Xilio's first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional tumor-selective cytokine programs using Xilio's proprietary technology.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
828 Winter St.
Waltham, MA 02451
USA
Phone
Undisclosed
Website
www.xiliotx.com
Email Address
Not Recorded
Overview
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company's proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body -- a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang.
Profile
Xilio Therapeutics LinkedIn Company Profile
Social Media
Xilio Therapeutics Company Twitter Account
Company News
Xilio Therapeutics News
Facebook
Xilio Therapeutics on Facebook
YouTube
Xilio Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rene Russo
  Rene Russo LinkedIn Profile  Rene Russo Twitter Account  Rene Russo News  Rene Russo on Facebook
Chief Medical Officer
Marty Huber
  Marty Huber LinkedIn Profile  Marty Huber Twitter Account  Marty Huber News  Marty Huber on Facebook
Chief Operating Officer
Joseph Farmer
  Joseph Farmer LinkedIn Profile  Joseph Farmer Twitter Account  Joseph Farmer News  Joseph Farmer on Facebook
President
Timothy Clackson
  Timothy Clackson LinkedIn Profile  Timothy Clackson Twitter Account  Timothy Clackson News  Timothy Clackson on Facebook
VP - R & D
Ronan O'Hagan
  Ronan O'Hagan LinkedIn Profile  Ronan O'Hagan Twitter Account  Ronan O'Hagan News  Ronan O'Hagan on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/3/2020: Thought Machine venture capital transaction
Next: 3/3/2020: Immunocore venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.